
    
      This study will have 2 phases.

      Phase 1:

      The phase 1 portion of this study is to establish the recommended phase 2 dose (RP2D) of
      gilteritinib given in combination with atezolizumab.

      Phase 2:

      The phase 2 portion of the study will treat patients with gilteritinib and atezolizumab at
      the RP2D and will enroll in two stages. The first stage will evaluate the remission rate and
      if a minimum rate is achieved, a second stage of enrollment will continue.
    
  